Show source-provided references
5. New strategies for the treatment of intervertebral disc degeneration: Cell, exosome, gene, and tissue engineering
8. Novel therapeutic strategies for degenerative disc disease: Review of cell biology and intervertebral disc cell therapy
10.1177/2050312118761674 ↗10. Clinical practice guidelines for the noninvasive management of low back pain: A systematic review by the ontario protocol for traffic injury management (OPTIMa) collaboration
10.1002/ejp.931 ↗12. The emerging roles of nanocarrier drug delivery system in treatment of intervertebral disc degeneration-current knowledge, hot spots, challenges and future perspectives
10.2147/dddt.s448807 ↗14. Construction of MOFs nanoplatform with pH-triggered release of protocatechuic acid for intervertebral disc degeneration therapy
10.1016/j.matdes.2022.111493 ↗15. Small molecule-based treatment approaches for intervertebral disc degeneration: Current options and future directions
10.7150/thno.48987 ↗17. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1
10.1038/nature25986 ↗19. The nucleotide sensor ZBP1 and kinase RIPK3 induce the enzyme IRG1 to promote an antiviral metabolic state in neurons
10.1016/j.immuni.2018.11.017 ↗20. Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling
10.1096/fj.201900887rr ↗21. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production
10.1073/pnas.1218599110 ↗24. Mechanobiology of the human intervertebral disc: Systematic review of the literature and future perspectives
10.3390/ijms24032728 ↗25. Efficient oral insulin delivery enabled by transferrin-coated acid-resistant metal-organic framework nanoparticles
10.1126/sciadv.abm4677 ↗27. Tailoring electron-rich fluorescent supramolecular organic frameworks for efficient capture and visual monitoring of iodine
10.1002/adfm.202413694 ↗31. MOF nanoparticles with encapsulated autophagy inhibitor in controlled drug delivery system for antitumor
10.1021/acsami.7b16522 ↗33. Inherent anchorages in UiO-66 nanoparticles for efficient capture of alendronate and its mediated release
10.1039/c4cc02570a ↗34. Defect-assisted loading and docking conformations of pharmaceuticals in metal–organic frameworks
10.1002/anie.202010231 ↗37. Nanoscale metal–organic frameworks for the Co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells
10.1021/ja4098862 ↗38. Organelle-specific triggered release of immunostimulatory oligonucleotides from intrinsically coordinated DNA–metal–organic frameworks with soluble exoskeleton
10.1021/jacs.7b07895 ↗40. Tale of COF-on-MOF composites with structural regulation and stepwise luminescence enhancement
10.1021/acsami.2c12606 ↗42. Unusual and highly tunable missing-linker defects in zirconium metal–organic framework UiO-66 and their important effects on gas adsorption
10.1021/ja404514r ↗45. Molecular identification and quantification of defect sites in metal-organic frameworks with NMR probe molecules
10.1038/s41467-022-32809-9 ↗47. Efficacy of hyaluronic acid on intervertebral disc inflammation: An in vitro study using notochordal cell lines and human disc cells
10.1002/jor.24933 ↗48. A pH/cellulase dual stimuli-responsive cellulose-coated metal–organic framework for eco-friendly fungicide delivery
10.1016/j.cej.2023.142190 ↗49. A general post-synthetic modification approach of amino-tagged metal–organic frameworks to access efficient catalysts for the Knoevenagel condensation reaction
10.1039/c5ta00816f ↗51. Correlation between lactate levels and pH in discs of patients with lumbar rhizopathies
10.1007/bf02146615 ↗53. The cellular and molecular biology of the intervertebral disc: A clinician’s primer
55. The extracellular matrix: Structure, composition, age-related differences, tools for analysis and applications for tissue engineering
10.1177/2041731414557112 ↗60. The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: A review
61. Oxidative stress in intervertebral disc degeneration: Molecular mechanisms, pathogenesis and treatment
10.1111/cpr.13448 ↗65. Balanced basal-levels of ROS (redox-biology), and very-low-levels of pro-inflammatory cytokines (cold-inflammaging), as signaling molecules can prevent or slow-down overt-inflammaging, and the aging-associated decline of adaptive-homeostasis
10.1016/j.exger.2022.112067 ↗66. Anti-inflammatory mechanisms of suppressors of cytokine signaling target ROS via NRF-2/thioredoxin induction and inflammasome activation in macrophages
10.5483/bmbrep.2020.53.12.161 ↗68. NF-κB signaling pathway in controlling intervertebral disk cell response to inflammatory and mechanical stressors
10.2522/ptj.20150045 ↗70. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: An in situ zymographic and gene therapy study
10.1186/ar2282 ↗71. Inhibiting tumor necrosis factor-alpha at time of induced intervertebral disc injury limits long-term pain and degeneration in a rat model
10.1002/jsp2.1014 ↗72. Inhibiting IκB kinase-β downregulates inflammatory cytokines in injured discs and neuropeptides in dorsal root ganglia innervating injured discs in rats
10.1097/brs.0000000000000374 ↗